Sabina Y van der Zanden

8PUBLICATIONS
36CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Pharmaceutical delivery technologiesInnate immunityBiologically active molecules
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jan 19, 2026
Cell cycle arrest enhances CD8+ T cell effector function by potentiating glucose metabolism and IL-2 signaling.

Floortje J van Haften, Tetje C van der Sluis, Hanna S Hepp

|Sep 03, 2025
Manipulating anthracyclines for deeper tissue penetration and implications for glycolytic tissues.

Erik R Abels, Esther Ter Linden, Jos H T Rohling

|Aug 01, 2024
Novel N,N-Dimethyl-idarubicin Analogues Are Effective Cytotoxic Agents for ABCB1-Overexpressing, Doxorubicin-Resistant Cells.

Merle A van Gelder, Yufeng Li, Dennis P A Wander

|Dec 13, 2023
Balanced Epigenetic Regulation of MHC Class I Expression in Tumor Cells by the Histone Ubiquitin Modifiers BAP1 and PCGF1.

Ruud H Wijdeven, Sietse J Luk, Tom A W Schoufour

|May 28, 2022
Induction of Fatigue by Specific Anthracycline Cancer Drugs through Disruption of the Circadian Pacemaker.

Yumeng Wang, Sabina Y van der Zanden, Suzanne van Leerdam

|Oct 16, 2020
Doxorubicin and Aclarubicin: Shuffling Anthracycline Glycans for Improved Anticancer Agents.

Dennis P A Wander, Sabina Y van der Zanden, Gijsbert A van der Marel

Pageof 2